STI Management

Frontline STI Management: Clinical Imperatives for FNP Practice

Sexually transmitted infections (STIs) remain a significant public health concern, with over 2.5 million cases of chlamydia, gonorrhea, and syphilis reported in the United States annually[1]. As a Family Nurse Practitioner (FNP), you will be on the front line of STI screening, diagnosis, treatment, and prevention in primary care settings. This topic is high-yield for the FNP certification exam, with frequent questions on screening guidelines, treatment regimens, and patient counseling.

Effective STI management requires a comprehensive approach: risk assessment, evidence-based screening, appropriate diagnostic testing, timely treatment, partner management, and prevention education. Mastery of this content directly improves patient outcomes and reduces community transmission.

Essential Terminology for STI Diagnosis and Partner Management

  • Screen – Testing asymptomatic individuals based on age, risk factors, or prevalence.
  • Diagnostic test – Testing individuals with signs or symptoms suggestive of an STI.
  • Incubation period – Time between exposure and symptom onset or test positivity; impacts timing of testing.
  • Window period – Time after infection during which a test may be negative despite infection (especially for HIV and syphilis).
  • Expedited partner therapy (EPT) – Providing treatment for partners of patients with chlamydia or gonorrhea without prior clinical evaluation; allowed in many states[1].
  • Co-infection – Presence of multiple STIs simultaneously (e.g., gonorrhea with chlamydia; syphilis with HIV).
  • Rectal and pharyngeal infections – Often asymptomatic but require specific site testing based on exposure history.

Foundational Strategies in STI Risk Assessment and Testing

Risk Assessment and Universal Precautions

  • Take a sexual history using open-ended, nonjudgmental questions (e.g., "Are you sexually active? With men, women, or both?").
  • Document type of sexual contact: vaginal, anal, oral; use of barrier protection; number of partners; history of STIs.
  • Use standard precautions for specimen collection and handling.

Screening Recommendations (CDC and USPSTF)

  • Chlamydia & Gonorrhea – Annual screening for all sexually active women <25 years; older women with risk factors (new partner, multiple partners, inconsistent condom use) [1][2].
  • Syphilis – Screen all pregnant women at first prenatal visit; screen high-risk populations (MSM, people with HIV, commercial sex workers).
  • HIV – Routine screening for everyone aged 13–64; repeat annually for high-risk groups[2].
  • HPV – Screen with Pap and HPV cotesting per cervical cancer guidelines (age 25–65).
  • Hepatitis B and C – HBsAg screening in pregnancy; HCV screening once for all adults born 1945–1965 or with risk factors.

Diagnostic Testing Methods

  • Nucleic Acid Amplification Tests (NAATs) – Gold standard for C. trachomatis and N. gonorrhoeae; high sensitivity/specificity; can use urine, vaginal swab (self-collected acceptable), cervical, or urethral specimens[1].
  • Serology – Used for syphilis (nontreponemal RPR/VDRL for screening; treponemal FTA-ABS/TP-PA for confirmation), HIV (antigen/antibody combo or rapid test), HSV (type-specific IgG – not recommended for low-prevalence populations), HBV/HCV.
  • Wet mount microscopy – For Trichomonas vaginalis (motile flagellates), but NAAT is more sensitive.
  • Urine NAAT – Convenient, sensitive; preferred in asymptomatic screening.

Clinical Presentations and Asymptomatic Infection Patterns

STICommon SymptomsAsymptomatic (%)
ChlamydiaVaginal discharge, dysuria, postcoital bleeding, abdominal pain; men: urethral discharge, dysuria70–80% women; 50% men
GonorrheaSimilar to chlamydia; may include pharyngeal or rectal pain~80% women; ~10% men
Syphilis (primary)Painless chancre at inoculation site (genital, anal, oral)Can be overlooked; often painless
TrichomoniasisFrothy yellow-green discharge, vulvar irritation, dyspareunia; "strawberry cervix"50–70% asymptomatic
HIV (acute)Fever, lymphadenopathy, pharyngitis, rash, myalgia (mononucleosis-like) 2–4 weeks post-exposureEarly may be subclinical
HSV-2Painful vesicles/ulcers; prodrome of tingling; recurrent outbreaksMany seropositive without recognized outbreaks
HPV (low-risk)Genital warts (flesh-colored, cauliflower-like)Most infections clear spontaneously

Adapted from CDC STI Treatment Guidelines[1].

Systematic Diagnostic Workup for Suspected STIs

  1. Obtain a thorough sexual history – Types of sexual activity, number of partners, use of protective measures, prior STI history, vaccination status (HPV, HBV).
  2. Perform targeted physical exam – Inspect genital, anal, and oral areas for lesions, discharge, warts, or lymphadenopathy; bimanual exam if abdominal/pelvic pain present. [3]
  3. Order appropriate tests based on exposure and symptoms – Vaginal or urine NAAT for CT/GC; serum RPR for syphilis; HIV 4th-gen antigen/antibody; type-specific HSV IgG if active lesions or known exposure.
  4. Test for co-infections – If gonorrhea diagnosed, treat presumptively for chlamydia unless NAAT rules it out. If syphilis diagnosed, test for HIV. [1]
  5. Pregnancy test – Always in reproductive-age women before treatment options, especially doxycycline use (contraindicated in pregnancy).
  6. Consider extragenital testing – Rectal and pharyngeal NAAT for MSM and women with receptive anal/oral exposure. [1]

First-Line Antibiotic Regimens and Partner Management Strategies

First-Line Antibiotic Regimens (CDC 2021)[1]

STIRecommended RegimenAlternative
Chlamydia (uncomplicated)Azithromycin 1 g PO × 1 OR Doxycycline 100 mg PO BID × 7 daysLevofloxacin 500 mg PO daily × 7 days
Gonorrhea (uncomplicated)Ceftriaxone 500 mg IM × 1 (1 g if >150 kg)Cefixime 800 mg PO × 1 (not for pharyngeal)
Syphilis (primary/secondary)Benzathine penicillin G 2.4 million units IM × 1Doxycycline 100 mg PO BID × 14 days (if penicillin allergy, non-pregnant)
TrichomoniasisMetronidazole 2 g PO × 1 OR Tinidazole 2 g PO × 1Metronidazole 500 mg PO BID × 7 days
Pelvic Inflammatory Disease (outpatient)Ceftriaxone 500 mg IM × 1 + Doxycycline 100 mg PO BID × 14 days ± Metronidazole 500 mg PO BID × 14 days–

Partner Management and Prevention

  • Expedited partner therapy (EPT) – Recommended for heterosexual partners of CT/GC patients when compliance ensured and state laws permit[1].
  • Abstinence – Advise no sexual activity for 7 days after completing treatment and until symptoms resolve.
  • Condom promotion – Consistent use reduces STI transmission but does not eliminate risk of HSV/HPV.
  • Vaccination – HPV vaccine (9-valent) up to age 45; HBV vaccine series.
  • HIV PrEP – Discuss with high-risk patients (condomless sex, MSM, people with STIs).

Adverse Effects, Treatment Failures, and Long-Term Sequelae

  • Drug allergies – Always confirm history of anaphylaxis to penicillin (contraindication to ceftriaxone) or doxycycline (photosensitivity, esophageal ulceration).
  • Jarisch-Herxheimer reaction – Fever, myalgia, headache within 24 hours of syphilis treatment; reassure it is self-limited.
  • Treatment failure – Retest for CT/GC at 3–4 weeks if symptoms persist; check for reinfection vs. resistance.
  • PID and infertility – Untreated chlamydia/gonorrhea can ascend to upper tract; scarring of fallopian tubes increases risk of ectopic pregnancy and infertility.
  • Congenital syphilis – Prevent by screening all pregnant women; treat early with penicillin.
  • HIV transmission – STIs facilitate HIV acquisition; urgent testing and linkage to care if HIV+.

Critical Distinctions for Certification Exam Success

  • Know the screening ages – Chlamydia/gonorrhea in women <25; HIV 13–64; syphilis in pregnancy.
  • Doxycycline vs. azithromycin – Doxycycline is now preferred for chlamydia due to lower resistance; azithromycin still acceptable but risk of macrolide resistance is rising[1].
  • Ceftriaxone dosing – Increased to 500 mg (up from 250 mg) for gonorrhea due to increasing MICs; 1 g for obese patients.
  • Syphilis serology – Use same nontreponemal test for titer monitoring (e.g., RPR); a 4-fold decline (e.g., 1:32 → 1:8) indicates adequate treatment.
  • HIV testing – 4th-gen antigen/antibody tests detect earlier than 3rd-gen; window period reduced to ~18 days.
  • Herpes – Type-specific IgG serology not recommended for general screening; use only if symptoms or known exposure. [1]
  • Trich treatment in pregnancy – Metronidazole is safe in all trimesters; tinidazole is category C – avoid first trimester if possible.
  • CDC updates frequently – Exam content based on 2021 guidelines; always check latest recommendations.

References

  1. Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187. https://doi.org/10.15585/mmwr.rr7004a1
  2. US Preventive Services Task Force. Screening for Chlamydia and Gonorrhea: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;326(10):949-956. https://doi.org/10.1001/jama.2021.14057
  3. Schuiling KD, Likis FE. Women’s Gynecologic Health. 3rd ed. Burlington, MA: Jones & Bartlett Learning; 2017. https://pubmed.ncbi.nlm.nih.gov/27876431/
  4. Centers for Disease Control and Prevention. Expedited Partner Therapy (EPT). Updated 2023. https://www.cdc.gov/sti/hcp/clinical-guidance/expedited-partner-therapy.html
  5. American College of Obstetricians and Gynecologists. Guidelines for Women's Health Care. 4th ed. Washington, DC: ACOG; 2014. https://catalog.nlm.nih.gov/discovery/fulldisplay/alma9916258203406676/01NLM_INST:01NLM_INST

Ready to test your knowledge?

Master the core responsibilities, scope of practice, and limitations for the Family Nurse Practitioner exam.

Start Practice Questions
Previous Topic Next Topic